Immune Pharmaceuticals Inc
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Immune Pharmaceuticals Inc
The average return for companies that went public in the US through the end of September was 49.4% as of 5 October. The fourth quarter started with three additional initial public offerings on 1 October.
Public Company Edition: Outside the US, Zai Lab raised more in its recent Hong Kong initial public offering – $766.4m – than PMV, Prelude, Taysha, Graybug and Greenwich combined. Also, Gilead priced debt to fund its $21bn Immunomedics buy and ADC Therapeutics raised $204m.
Public Company Edition: The former Allergan CEO is taking a special purpose acquisition corporation public to generate $460m for deals in familiar biopharma niches. Also, IPOs are expected to keep up a robust pace in the fall and Albireo raises $160m on the success of its drug for pediatric liver diseases.
Qpex licenses rights to its antibiotic portfolio in China to Brii Biosciences. Moberg and DongKoo partner on commercialization of onychomycosis therapy in Korea.
- Site Specific
- Topical Delivery
- Drug Delivery
- Nanotechnology, Chips, etc.
- Other Names / Subsidiaries
- EpiCept Corporation (Maxim Pharmaceuticals)
- Cytovia, Inc.
- Immune Pharmaceuticals Ltd.